Mysuru, December 9:- As part of various initiatives towards mitigating Covid-19, CSIR and Central Food Technological Research Institute (CFTRI) signed a Memorandum of Understanding (MoU) with Clevergene, a Bengaluru-based company for sequencing of the SARS-CoV-2 genome. It is expected that the study would provide insights into virus genome changes (mutations), evolution, epidemiology, and provide an understanding of the spatial and temporal information on infection dynamics of the SARS-CoV-2. Further, under the MoU, the development of novel diagnostics and vaccines for Covid-19 are envisaged.
CSIR-CFTRI has also established a COVID Testing Centre in Mysuru and on an average, more than 1000 samples are tested in a day. Further, CFTRI is also working on the development of novel dipstick and aptamer-based diagnostics in collaboration with private parties. Clevergene is a tech company offering genomics services for contract research and genetic diagnostics.
The MoU was exchanged recently between Dr B Manohar, chief scientist and adviser (M&A) and Tony Jose, co-founder and CEO, Clevergene, in a brief function held at the institute.
Dr Prakash M Halami, chief scientist and nodal officer and Dr P V Ravindra, in-charge coordinator, CFTRI-COVID Testing Laboratory, were present. (MR)